EUVIMEDEUVIMED entdecken
Crossref

Drug-drug interaction assessments of clinical transporter inhibition: Learnings from the Transporter Working Group of the International Consortium for Innovation and Quality in Pharmaceutical Development

Rucha S Sane, Pallabi Mitra, Yurong Lai, Cindy Yanfei Li, Hong Shen, Kimio Tohyama, Chester Costales, Laurent Salphati, Kelly M Mahar, Daniel A J Bow, James M Vergis, Jochen Brumm und 15 weitere

Drug Metabolism and Disposition · 2026-04 · 54 (4) · 100255

DOI: 10.1016/j.dmd.2026.100255 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2026-04. Verfasst von Rucha S Sane und 26 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Genentech, Inc., South San Francisco, California. Electronic address: sane.rucha@gene.com. Hauptthemen laut MEDLINE: Membrane Transport Proteins, Drug Development. Die Arbeit nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The International Consortium for Innovation and Quality for Pharmaceutical Development Transporter Working Group analyzed survey results submitted by 17 member companies describing in vitro and in vivo data for drug-drug interactions (DDI) based on drug transporter inhibition. Trends for in vitro-in vivo correlation and impact of physicochemical properties on potential for clinical inhibition were explored for intestinal (P-glycoprotein/breast cancer resistance protein), hepatic (organic anion transporting polypeptide [OATP]1Bs), and renal (organic cation transporter 2/organic anion transporter/multidrug and toxin extrusion proteins) drug transporters. The dataset comprised 58 clinical inhibition studies involving 42 compounds as DDI perpetrators, balanced across Biopharmaceutics Classification System/Biopharmaceutical Drug Disposition Classification System classes and therapeutic areas. Studies were often triggered by in vitro data indicating potential clinical DDI risk or based on anticipated comedications. Overall findings suggest that the magnitude of transporter-mediated drug interactions was relatively low for the majority of the studies ( 2-fold were only reported for statin probe substrates with OATP1B, breast cancer resistance protein, and/or CYP3A4 inhibitors. Consistent with previous reports, low false negative and high false positive rates were observed when applying static cutoff criteria suggested by regulatory agencies for both P-glycoprotein and OATPs. Lastly, the physicochemical analyses demonstrated that clinical inhibitors of P-glycoprotein and breast cancer resistance protein tended to be more lipophilic than noninhibitors (median log D, 2.9 vs 1.7), and OATP1B1/1B3 inhibitors also tended to have higher molecular weights (median, 700 vs 530 Da). This work highlights current strategies for identifying transporter-mediated DDI risks and the need to incorporate additional approaches, such as biomarker profiling and predictive modeling, for nuanced insights. SIGNIFICANCE STATEMENT: A diverse dataset comprising 58 clinical studies evaluating transporter inhibition showed that inhibitors of P-glycoprotein, breast cancer resistance protein, and organic anion transporting polypeptide-1B transporters tend to be more lipophilic and larger than noninhibitors. Greater than 2-fold interactions were generally observed with substrates involving multipathway inhibitors of organic anion transporting polypeptide-1B, breast cancer resistance protein, and/or CYP3A. Low false negative and high false positive rates were observed when applying the static cutoff values in the regulatory guidance, indicating adequacy of static approach with a role for additional approaches such as modeling or biomarkers for nuanced insights.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Membrane Transport ProteinsDrug DevelopmentDrug InteractionsHumansPharmaceutical PreparationsAnimalsBiological TransportOrganic Anion Transporters

Stichwörter der Autor:innen

BCRPDrug-drug interactionsInhibitionOATP1B1P-gpTransporters

Substanzen

Membrane Transport ProteinsPharmaceutical PreparationsOrganic Anion Transporters

Autor:innen und Institutionen

  • Clinical Pharmacology, Genentech, Inc., South San Francisco, California. Electronic address: sane.rucha@gene.com.
  • Department of Clinical Pharmacology & Nonclinical Safety Sciences, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut.
  • Drug Metabolism, Gilead Sciences, Inc, Foster City, California.
  • Department of Pharmacokinetics and Drug Metabolism, Amgen Inc, South San Francisco, California.
  • Department of Drug Metabolism and Pharmacokinetics, Bristol Myers Squibb Research and Development, Princeton, New Jersey.
  • Takeda Pharmaceutical Company Limited, Fujisawa, Japan.

Zitieren

APA

Sane, R. S., Mitra, P., Lai, Y., Li, C. Y., Shen, H., Tohyama, K., Costales, C., Salphati, L., Mahar, K. M., Bow, D. A. J., Vergis, J. M., Brumm, J., Taskar, K., Chanteux, H., Fang, Z., Liang, X., Park, S. H., Hanna, I., Thakkar, N., …, & Hillgren, K. M. (2026). Drug-drug interaction assessments of clinical transporter inhibition: Learnings from the Transporter Working Group of the International Consortium for Innovation and Quality in Pharmaceutical Development. Drug Metabolism and Disposition, 54(4), 100255. https://doi.org/10.1016/j.dmd.2026.100255

Vancouver

Sane RS, Mitra P, Lai Y, Li CY, Shen H, Tohyama K, et al. Drug-drug interaction assessments of clinical transporter inhibition: Learnings from the Transporter Working Group of the International Consortium for Innovation and Quality in Pharmaceutical Development. Drug Metabolism and Disposition. 2026;54(4):100255. doi:10.1016/j.dmd.2026.100255

BibTeX
@article{Sane2026,
  author = {Sane, Rucha S and Mitra, Pallabi and Lai, Yurong and Li, Cindy Yanfei and Shen, Hong and Tohyama, Kimio and Costales, Chester and Salphati, Laurent and Mahar, Kelly M and Bow, Daniel A J and Vergis, James M and Brumm, Jochen and Taskar, Kunal and Chanteux, Hugues and Fang, Zhizhou and Liang, Xiaomin and Park, Seong Hee and Hanna, Imad and Thakkar, Nilay and Chu, Xiaoyan and Hop, Cornelis E C A and Rollison, Helen E and Taub, Mitchell E and Kimoto, Emi and Fenner, Katherine S and Xu, Christine and Hillgren, Kathleen M},
  title = {Drug-drug interaction assessments of clinical transporter inhibition: Learnings from the Transporter Working Group of the International Consortium for Innovation and Quality in Pharmaceutical Development},
  journal = {Drug Metabolism and Disposition},
  year = {2026},
  volume = {54},
  number = {4},
  pages = {100255},
  doi = {10.1016/j.dmd.2026.100255}
}
Kostenlos starten →